BOTOX - Laurence-Moon-Bardet-Biedl

Botulinum toxin
Bardet-Biedl Syndrome
Selective Laser Trabeculoplasty

The intraneuronal mechanism of action of BTX-A involves the proteolytic cleavage by its light chain of the protein SNAP 25. With syntaxin, synaptobrevin and synaptostagmin, these neuronal proteins form the core complex postulated to coordinate regulated vesicularfusion for neurotransmitter release. By preventing the assembly of this synaptic core complex, botulinum toxin inhibits neurotransmitter release, notably for cholinergic and catecholaminergic cells, but this can also occur for several classes of neutransmitters at central and peripheral neurones, once the toxin is injected intraneuronally in vitro...

JM Gracies

LINKS

BARDET-BIEDL SYNDROME

This condition is characterized by mental retardation, pigmentary retinopathy, polydactyly, obesity, and hypogenitalism, and has incorrectly been called LMBB (Laurence-Moon-Bardet-Biedl) syndrome. Ammann (1970) pointed out that these features were present in the patients of Biedl (1922) and Bardet (1920), but that the patients of Laurence and Moon had a distinct disorder with ...

LINKS

Selective Laser Trabeculoplasty: Clinical Results - A One Year Prospective Study 29/06/00
H. Gracies , Y. Lachkar, J. Da Cunha, J. Kopel
Glaucoma Institute - Foundation Hospital Saint-Joseph, Paris - France
Selective laser trabeculoplasty: first clinical results 11/02/98
H. Gracies, Y. Lachkar, J. Kopel, F. Kotobi, Ph. Demailly
Glaucoma Institute, Saint Joseph Foundation, Paris, France

Purpose: Selective laser trabeculoplasty (SLT) is a new technique developed to selectively target pigmented trabecular meshwork. We investigated the safety and efficacy of this technique to lower intraocular pressure (IOP).
Methods: Fifty nine eyes with uncontrolled open angle glaucoma (OAG) with prior medical therapy were treated with the Coherent Selecta 7000 ^TM(Coherent Inc., Palo Alto, CA), a frequency doubled Q switched Nd:Yag laser. Approximately 110 laser spots were applied over 360° of the trabecular meshwork. Efficacy was determined 5 weeks, 1 month, 3 months, 6 months and one year after the procedure.
Results: The average preoperative IOP was 25.05mmHg .Mean post operative IOP (at one year) was 15.76mmHg. Mean percentage reduction was 32.43% at 3 months after operation, 32.51% at six months and 33.51% at one year. Transient post operative pressure spike of 5mmHg or greater resolved in 24 hours was observed in 5 eyes.
Conclusion: SLT appears to be an effective and safe technique for lowering IOP and could be an alternative to Argon laser trabeculoplasty.
Purpose: Selective laser trabeculoplasty (SLT) is a new technique developed to selectively target pigmented trabecular meshwork. We investigated the safety and efficacy of this technique to lower intraocular pressure (IOP)
Methods : Twenty five eyes with uncontrolled open angle glaucoma (OAG) with prior medical therapy were treated with the Coherent Selecta 7000TM (Coherent Inc , Palo Alto, CA), a frequency doubled Q switched Nd:Yag laser. 9 eyes (group 1) were considered with an angle pigmentation grade at 3 or 4 and 16 with a pigmentation at 1 or 2 (group 2 ). Approximately 110 laser spots were applied over 360° of the TM. Efficacy was determined 5 weeks after the procedure.
Results . The average preoperative IOP was 24.56 mm Hg .The mean post operative IOP (at 5 weeks) was 16.44 (-31.63 %).The mean percentage reduction was 31.1 in group 2 and 32.6 in group 1. Transient post operative pressure spike (< 10 mm Hg) resolved in 24 hours was observed in 2 eyes.
Conclusion: SLT appears to be and effective and safe technique for lowering IOP and could be an alternative to Argon laser trabeculoplasty.

LINKS

Use our comments form